Experimental Study of the Efficiency of Impaza on the Model of Chronic Aseptic Prostatic Inflammation

• Published in: Bulletin of experimental biology and medicine Vol. 154; no. 2; pp. 217 - 219
• Main Authors: Borovskaya, T. G., Fomina, T. I., Pakhomova, A. V., Ermolaeva, L. A., Poluektova, M. E., Zhavbert, E. S., Dugina, Ju. L., Kheifets, I. A., Epstein, O. I.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-12-2012; Springer; Springer Nature B.V
• Subjects: Animals; Antibodies - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cell Biology; Erectile Dysfunction; Inflammation; Internal Medicine; Laboratory Medicine; Male; Nitric Oxide Synthase Type III - metabolism; Pathology; Pharmacology and Toxicology; Plant Extracts - therapeutic use; Prostatitis - drug therapy; Prostatitis - metabolism; Rats; Serenoa - chemistry; Serenoa repens; Sexual disorders; chronic prostatitis; ultra-low doses of antibodies against endothelial NO-synthase; erectile dysfunction
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-012-1916-0

We compared the efficacy of Impaza (antibodies against endothelial NO-synthase in ultra-low doses) and
Serenoa repens
on the rat model of chronic aseptic prostatic inflammation. Administration of
Serenoa repens
in a dose of 50 mg/kg for 1.5 months prevented the development of prostate sclerosis and increased luminal area, but did delay the development of atrophic processes. In animals treated with Impaza (3 ml/kg for 1.5 months), atrophic changes in the prostate gland were practically absent. These findings indicate that Impaza can be used in complex therapy of abacterial prostatitis.